Tuesday, August 29, 2023 Daily Archives

eBook: Viral Vectors — Progress Toward Production Platforms

by

After decades of research and development (R&D) and despite more than a few clinical setbacks, viral-vector gene therapies finally are making headway into the marketplace. However, cost considerations still reverberate around the biopharmaceutical industry. Scientists recognize that nonoptimal manufacturing is implicated in the high prices for gene-therapy products. For instance, adenoassociated virus (AAV) and other such gene-delivery systems are produced at much lower scales than are monoclonal antibodies (MAbs) and other recombinant proteins — understandably so given the size and…

August 29, 2023

In brief: Sartorius and Repligen team on bioreactor system

by

The system combines Repligen’s alternating tangential flow (ATF) system with Sartorius’ BioStat reactor allowing an intensified upstream process for biomanufacturers, according to the firms. With Sartorius’ Biostat stirred-tank reactor (STR) reactor now equipped with Repligen’s hardware and software module, the firms claim intensified seed train and N perfusion implementation will be simpler and more efficient for customers. Furthermore, the firms claim the joint offering will enable better facility utilization for customers through the creation of a single point of control…

August 29, 2023

Bristol Myers taps cash rich Cellares for CAR-T processing

by

Having raised $255 million and laid ground on a third facility, cell therapy technology firm Cellares has added Bristol Myers Squibb to its Technology Adoption Partnership (TAP) program. It’s been a busy week for Californian firm Cellares, having raised money, expanded its footprint, and bolstered its customer base by bagging Big Biopharma Bristol Myers. Cellares, which leverages its modular and automated cell therapy platform – the Cell Shuttle – to address limitations in current advanced therapy manufacturing, will use $255…

August 29, 2023